Results of Hepatitis C Virus Treatment in Patients on Hemodialysis: Data From Published Meta-analyses in 2008

Taltavull, Teresa Casanovas; Baliellas, Carme; Garrit, Josep María Cruzado

doi:10.1016/j.transproceed.2009.06.140

Cited by 12 publications

(4 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As a result, the SVR rate was low. Casanovas Taltavull et al . reported a meta‐analysis with an overall SVR rate of 40% and an SVR rate in genotype 1 patients receiving peg‐IFN of 33%.…”

Section: Discussionmentioning

confidence: 99%

Interferon treatment for patients with chronic hepatitis C complicated with chronic renal failure receiving hemodialysis

Kojima¹,

Kakizaki²,

Hosonuma³

et al. 2013

J of Gastro and Hepatol

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Interferon treatment for patients with chronic hepatitis C complicated with chronic renal failure receiving hemodialysis

Kojima¹,

Kakizaki²,

Hosonuma³

et al. 2013

J of Gastro and Hepatol

View full text Add to dashboard Cite

show abstract

“…By way of contrast, 90% of an administered dose of interferon [87] and 61% of ribavirin [88] are excreted in urine. Accordingly, their adverse reactions are augmented in patients with low GFR, including the ribavirin-induced hemolytic anemia and the long list of interferon side effects [89] , mostly the hematopoietic.…”

Section: Managementmentioning

confidence: 99%

Hepatitis C and kidney disease: A narrative review

Barsoum

William

Khalil³

2017

Journal of Advanced Research

View full text Add to dashboard Cite

show abstract

“…In addition, the HCV genotype does not seem to have an impact on survival in kidney transplant recipients [49]. There are virtually no data on comparing treatment response of the various genotypes in patients on hemodialysis, but small studies do suggest that genotype 1 patients are able to achieve an SVR anywhere from 28% to 75% of the time with a 48-week course of PEG-IFN monotherapy [50–52]. …”

Section: Hcv Treatment In Renal Transplant Candidatesmentioning

confidence: 99%

Management of the Kidney Transplant Patient with Chronic Hepatitis C Infection

Tang

Walzer

Aggarwal

et al. 2011

International Journal of Nephrology

View full text Add to dashboard Cite

Chronic Hepatitis C (HCV) infection is an important cause of morbidity and mortality in patients with end-stage renal disease. Renal transplantation confers a survival advantage in HCV-infected patients. Renal transplant candidates with serologic evidence of HCV infection should undergo a liver biopsy to assess for fibrosis and cirrhosis. Patients with Metavir fibrosis score ≤3 and compensated cirrhosis should be evaluated for interferon-based therapy. Achievement of sustained virological response (SVR) may reduce the risks for both posttransplantation hepatic and extrahepatic complications such as de novo or recurrent glomerulonephritis associated with HCV. Patients who cannot achieve SVR and have no live kidney donor may be considered for HCV-positive kidneys. Interferon should be avoided after kidney transplant except for treatment of life-threatening liver injury, such as fibrosing cholestatic hepatitis. Early detection, prevention, and treatment of complications due to chronic HCV infection may improve the outcomes of kidney transplant recipients with chronic HCV infection.

show abstract

Results of Hepatitis C Virus Treatment in Patients on Hemodialysis: Data From Published Meta-analyses in 2008

Cited by 12 publications

References 13 publications

Interferon treatment for patients with chronic hepatitis C complicated with chronic renal failure receiving hemodialysis

Interferon treatment for patients with chronic hepatitis C complicated with chronic renal failure receiving hemodialysis

Hepatitis C and kidney disease: A narrative review

Management of the Kidney Transplant Patient with Chronic Hepatitis C Infection

Contact Info

Product

Resources

About